News & Updates

Show Multimedia Only

Rivaroxaban superior to metoprolol for migraine in patients with PFO

Three antithrombotic medications (aspirin, clopidogrel, and rivaroxaban) demonstrate noninferiority to metoprolol for responder rate (RR) in patients with migraine and patent foramen ovale (PFO), a study has shown. Rivaroxaban also delivers the highest RR without increasing major bleeding events.

Rivaroxaban superior to metoprolol for migraine in patients with PFO

a day ago

A leap forward towards more precise and individualized immunotherapy for glioblastoma

11 Aug 2026 by

Researchers from the Clinical Neuroscience Consortium (CNC), a collaborative platform jointly established by the University of Hong Kong (HKU) and Queen Mary Hospital in collaboration with the Hong Kong Genome Institute (HKGI), have achieved a major breakthrough in brain cancer research, uncovering thousands of previously unannotated isoforms and identifying potential targets for both precision therapeutics and personalized cancer vaccines.

A leap forward towards more precise and individualized immunotherapy for glioblastoma

11 Aug 2026

Oveporexton confers symptomatic, functional, cognitive benefits in narcolepsy type 1

10 Aug 2026 by

Treatment with the oral orexin receptor 2 (OX2R) agonist oveporexton improves symptom control, daily function, and cognitive outcomes in patients with narcolepsy type 1, according to pooled data from two phase III studies, The First Light and The Radiant Light.

Oveporexton confers symptomatic, functional, cognitive benefits in narcolepsy type 1

10 Aug 2026

Inhaled levodopa helps manage off episodes in PD, regardless of age

09 Aug 2026 by

Treatment with the inhaled levodopa formulation CVT-301 provides rapid motor symptom relief during off periods, with consistent efficacy seen across Parkinson’s disease (PD) patients of all ages, according to a post hoc analysis of three phase III trials.

Inhaled levodopa helps manage off episodes in PD, regardless of age

09 Aug 2026

Tau-targeting therapy for early AD gets a pass to phase III

07 Aug 2026 by

In the phase II CELIA trial, the investigational tau-targeting antisense oligonucleotide (ASO) diranersen has shown therapeutic potential in patients with early Alzheimer’s disease (AD), yielding substantial reductions in tau burden and slowing clinical decline despite missing its primary endpoint.

Tau-targeting therapy for early AD gets a pass to phase III

07 Aug 2026

Cannabinoid combination quells agitation in late-stage dementia patients

05 Aug 2026 by

The experimental combination of tetrahydrocannabinol (THC) plus cannabidiol (CBD) proves beneficial in reducing agitation in hospice care-eligible patients with late-stage dementia, according to the phase II LiBBY trial.

Cannabinoid combination quells agitation in late-stage dementia patients

05 Aug 2026

SMA treatment with risdiplam: Experience in HK

05 Aug 2026 by

Spinal muscular atrophy (SMA) is an inherited neuromuscular disorder that causes progressive muscle weakness and wasting, resulting in loss of motor function. The oral drug risdiplam demonstrated improvement or stabilization of motor function in clinical studies of patients with SMA. Professor Sophelia Chan of the Department of Paediatrics and Adolescent Medicine, University of Hong Kong, shared the latest published local findings on treatment outcomes with risdiplam in paediatric and adult patients with SMA.

SMA treatment with risdiplam: Experience in HK

05 Aug 2026

Prenatal ADHD medication use does not harm early developmental outcomes in offspring

04 Aug 2026

Children born to mothers with attention deficit/hyperactivity disorder (ADHD) who used associated medications during pregnancy do not seem to have adverse early childhood development, according to a retrospective study from the Netherlands.

Prenatal ADHD medication use does not harm early developmental outcomes in offspring

04 Aug 2026

Physical activity promotes long-term brain health

04 Aug 2026 by

Engaging in high levels of physical activity throughout adulthood may reduce the risk of dementia and preserve cognitive health.

Physical activity promotes long-term brain health

04 Aug 2026

Candesartan shows promise as first-line treatment for migraine

04 Aug 2026

Use of candesartan is both safe and effective, showing promise in the prevention of migraine headaches, suggests a study in the Philippines.

Candesartan shows promise as first-line treatment for migraine

04 Aug 2026

News & Updates

Showing Neurology articles

Showing

Specialty:

Rivaroxaban superior to metoprolol for migraine in patients with PFO

Rivaroxaban superior to metoprolol for migraine in patients with PFO

A leap forward towards more precise and individualized immunotherapy for glioblastoma

A leap forward towards more precise and individualized immunotherapy for glioblastoma

Oveporexton confers symptomatic, functional, cognitive benefits in narcolepsy type 1

Oveporexton confers symptomatic, functional, cognitive benefits in narcolepsy type 1

Inhaled levodopa helps manage off episodes in PD, regardless of age

Inhaled levodopa helps manage off episodes in PD, regardless of age

Tau-targeting therapy for early AD gets a pass to phase III

Tau-targeting therapy for early AD gets a pass to phase III

Cannabinoid combination quells agitation in late-stage dementia patients

Cannabinoid combination quells agitation in late-stage dementia patients

SMA treatment with risdiplam: Experience in HK

SMA treatment with risdiplam: Experience in HK

Prenatal ADHD medication use does not harm early developmental outcomes in offspring

Prenatal ADHD medication use does not harm early developmental outcomes in offspring

Physical activity promotes long-term brain health

Physical activity promotes long-term brain health

Candesartan shows promise as first-line treatment for migraine

Candesartan shows promise as first-line treatment for migraine